Teton Advisors’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Teton Advisors’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,750	Closed	-$17K	–	472
2019 Q2	$17K	Sell	1,750 -450	-20%	-$8.28K	﹤0.01%	469
2019 Q1	$59K	Hold	2,200	–	–	0.01%	460
2018 Q4	$50K	Hold	2,200	–	–	0.01%	457
2018 Q3	$121K	Hold	2,200	–	–	0.01%	456
2018 Q2	$157K	Buy	2,200 +50	+2%	+$3.53K	0.01%	437
2018 Q1	$132K	Buy	2,150 +650	+43%	+$57.1K	0.01%	428
2017 Q4	$189K	Hold	1,500	–	–	0.02%	393
2017 Q3	$205K	Hold	1,500	–	–	0.02%	391
2017 Q2	$214K	Hold	1,500	–	–	0.02%	384
2017 Q1	$276K	Hold	1,500	–	–	0.03%	353
2016 Q4	$121K	Buy	1,500 +300	+25%	+$23.7K	0.01%	384
2016 Q3	$92K	Hold	1,200	–	–	0.01%	452
2016 Q2	$103K	Buy	+1,200	New	+$110K	0.01%	470

Other funds holding TTPH

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Teton Advisors's TTPH Position: Q3 2019 in Review

Teton Advisors sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 1,750 shares — an estimated $17K sold.

Teton Advisors first reported a position in TTPH in Q2 2016 and held it in 13 quarters. The position peaked at $276K in Q1 2017. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

Teton Advisors reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Teton Advisors sold 1,750 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $17K.
Teton Advisors first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2016 and held it in 13 quarters.
Teton Advisors's Tetraphase Pharmaceuticals, Inc. position peaked at $276K in Q1 2017.
26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on Teton Advisors's 13F filing for Q3 2019, filed 1 Nov 2019.